HK1054924A1 - Carboxylic acid derivatives as ip antagonists - Google Patents

Carboxylic acid derivatives as ip antagonists

Info

Publication number
HK1054924A1
HK1054924A1 HK03107345A HK03107345A HK1054924A1 HK 1054924 A1 HK1054924 A1 HK 1054924A1 HK 03107345 A HK03107345 A HK 03107345A HK 03107345 A HK03107345 A HK 03107345A HK 1054924 A1 HK1054924 A1 HK 1054924A1
Authority
HK
Hong Kong
Prior art keywords
antagonists
carboxylic acid
acid derivatives
derivatives
carboxylic
Prior art date
Application number
HK03107345A
Other languages
English (en)
Inventor
Richard Leo Cournoyer
Paul Francis Keitz
Lee Edwin Lowrie Jr
Alexander Victor Muehldorf
Counde O'yang
Dennis Mitusgu Yasuda
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of HK1054924A1 publication Critical patent/HK1054924A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/56—Benzoxazoles; Hydrogenated benzoxazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/22—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
    • C07C311/02—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C311/08—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/21—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D215/14—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/18—Benzimidazoles; Hydrogenated benzimidazoles with aryl radicals directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D307/10—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/12—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/80—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Reproductive Health (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Ophthalmology & Optometry (AREA)
  • Virology (AREA)
  • Dermatology (AREA)
  • Otolaryngology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
HK03107345A 2000-03-16 2003-10-14 Carboxylic acid derivatives as ip antagonists HK1054924A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US19012900P 2000-03-16 2000-03-16
US24712900P 2000-11-10 2000-11-10
PCT/EP2001/002597 WO2001068591A1 (en) 2000-03-16 2001-03-08 Carboxylic acid derivatives as ip antagonists

Publications (1)

Publication Number Publication Date
HK1054924A1 true HK1054924A1 (en) 2003-12-19

Family

ID=26885804

Family Applications (1)

Application Number Title Priority Date Filing Date
HK03107345A HK1054924A1 (en) 2000-03-16 2003-10-14 Carboxylic acid derivatives as ip antagonists

Country Status (22)

Country Link
US (3) US6693098B2 (ru)
EP (1) EP1265853A1 (ru)
JP (1) JP3938689B2 (ru)
KR (1) KR100523119B1 (ru)
CN (1) CN1241909C (ru)
AR (1) AR028252A1 (ru)
AU (2) AU5216801A (ru)
BR (1) BR0109235A (ru)
CA (1) CA2401502C (ru)
CZ (1) CZ20023422A3 (ru)
HK (1) HK1054924A1 (ru)
HR (1) HRP20020733A2 (ru)
HU (1) HUP0300188A3 (ru)
IL (1) IL151478A (ru)
MA (1) MA27679A1 (ru)
MX (1) MXPA02008931A (ru)
NO (1) NO328526B1 (ru)
NZ (1) NZ521028A (ru)
PL (1) PL207869B1 (ru)
RU (1) RU2268258C2 (ru)
WO (1) WO2001068591A1 (ru)
YU (1) YU68102A (ru)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2401502C (en) * 2000-03-16 2010-09-21 F. Hoffmann-La Roche Ag Carboxylic acid derivatives as ip antagonists
ATE309994T1 (de) * 2001-03-02 2005-12-15 Hoffmann La Roche Alkoxycarbonylaminobenzoesäure- oder alkoxycarbonylaminotetrazolylphenylderivate als ip-antagonisten
JP2004526721A (ja) * 2001-03-02 2004-09-02 エフ．ホフマン−ラ　ロシュ　アーゲー Ｉｐアンタゴニストとしてのアルコキシカルボニルアミノヘテロアリールカルボン酸誘導体
JP4705756B2 (ja) * 2002-02-07 2011-06-22 仁 遠藤 芳香族アミノ酸誘導体及び医薬組成物
GB2389580A (en) * 2002-06-12 2003-12-17 Bayer Ag 2-Naphthamide PGI2 antagonists
GB2389582A (en) * 2002-06-13 2003-12-17 Bayer Ag Pharmaceutically active carboxamides
AU2003276201A1 (en) * 2002-11-11 2004-06-03 Bayer Healthcare Ag Phenyl or heteroaryl amino alkane derivatives as ip receptor antagonist
SI1587821T1 (sl) * 2002-12-19 2009-02-28 Scripps Research Inst Sestavki in postopki za stabiliziranje transtiretina in zaviranje napaäśnega zvijanja transtiretina
EP1594846A1 (en) * 2003-02-10 2005-11-16 Bayer HealthCare AG Bis(hetero)aryl carboxamide derivatives for use as pgi2 antagonists
US20060171945A1 (en) * 2003-02-14 2006-08-03 Critchley Hilary Octavia D Ip receptor antagonists for the treatment of pathological uterine conditions
DE10332560B4 (de) * 2003-07-11 2010-07-08 Chiracon Gmbh Verfahren zur Herstellung von ß- Heteroaryl-2-alanin-Verbindungen über 2-Amino-2-(heteroarylmethyl)-carbonsäure-Verbindungen
US7256207B2 (en) * 2003-08-20 2007-08-14 Irm Llc Inhibitors of cathepsin S
WO2005112913A1 (en) 2004-05-20 2005-12-01 The Scripps Research Institute Transthyretin stabilization
WO2006029735A1 (en) * 2004-09-15 2006-03-23 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with prostaglandin 12 receptor (ptgir)
BRPI0709164A2 (pt) * 2006-03-24 2011-06-28 Wyeth Corp métodos para modulação da função da bexiga
WO2008034016A2 (en) * 2006-09-15 2008-03-20 Foldrx Pharmaceuticals, Inc. Assays for detecting native-state proteins and identifying compounds that modulate the stability of native-state proteins
TWI449040B (zh) * 2006-10-06 2014-08-11 Crocus Technology Sa 用於提供內容可定址的磁阻式隨機存取記憶體單元之系統及方法
KR20240024285A (ko) * 2008-03-18 2024-02-23 아레나 파마슈티칼스, 인크. 프로스타시클린 （ｐｇｉ２） 수용체와 관련된 장애의 치료에 유용한 상기 수용체의 조절제
EP2109111B1 (en) * 2008-04-07 2011-12-21 Crocus Technology S.A. System and method for writing data to magnetoresistive random access memory cells
EP2124228B1 (en) * 2008-05-20 2014-03-05 Crocus Technology Magnetic random access memory with an elliptical junction
US8031519B2 (en) * 2008-06-18 2011-10-04 Crocus Technology S.A. Shared line magnetic random access memory cells
GB0907551D0 (en) * 2009-05-01 2009-06-10 Univ Dundee Treatment or prophylaxis of proliferative conditions
CN103097385B (zh) * 2010-07-14 2016-08-03 诺华股份有限公司 Ip受体激动剂杂环化合物
JP5705984B2 (ja) * 2010-08-23 2015-04-22 ノバルティス アーゲー Ｎｅｐ阻害剤を製造するための中間体の調製方法
CN103781770B (zh) 2011-09-16 2016-04-13 辉瑞公司 转甲状腺素蛋白解离抑制剂的固体形式
TW201335160A (zh) * 2012-01-13 2013-09-01 Novartis Ag Ｉｐ受體激動劑之雜環化合物
WO2014143592A1 (en) 2013-03-12 2014-09-18 Allergan, Inc. Inhibition of neovascularization by inhibition of prostanoid ip receptors
WO2014143591A1 (en) 2013-03-12 2014-09-18 Allergan, Inc. Inhibition of neovascularization by simultaneous inhibition of prostanoid ip and ep4 receptors
NZ736978A (en) 2015-07-24 2019-06-28 Newlink Genetics Corp Salts and prodrugs of 1-methyl-d-tryptophan
ES2965069T3 (es) 2017-03-01 2024-04-11 Arena Pharm Inc Composiciones que comprenden agonistas del receptor de PGI2 y procesos para la preparación de las mismas
EP3746134A1 (en) 2018-02-02 2020-12-09 Maverix Oncology, Inc. Small molecule drug conjugates of gemcitabine monophosphate
CN111408314B (zh) * 2020-04-17 2021-08-10 甘肃智仑新材料科技有限公司 一种含炔基阳离子表面活性剂及其制备方法
CA3212050A1 (en) * 2021-03-18 2022-09-22 Weizhen Wang Methods and compositions for treating eye diseases

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB895344A (en) 1957-08-30 1962-05-02 Ciba Ltd Method of temporary protection of hydroxy, mercapto and amino groups
US3875207A (en) 1967-01-25 1975-04-01 Ciba Geigy Corp Process for the temporary protection of amino groups in peptide syntheses
FR1554051A (ru) 1967-01-25 1969-01-17
DE1934783A1 (de) 1969-07-09 1971-01-28 Bayer Ag Biphenylisopropyloxycarbonylfluorid und seine Verwendung zur Acylierung von Aminosaeuren
DE2641060A1 (de) 1976-09-11 1978-03-16 Hoechst Ag Beta-lactamverbindungen und verfahren zu ihrer herstellung
US4145337A (en) 1977-10-11 1979-03-20 Hoffmann-La Roche Inc. Aminoethylglycine containing polypeptides
JPH0672985B2 (ja) 1986-05-29 1994-09-14 株式会社ハツコウ メガネ枠フイツテイング調整システム
NZ221729A (en) 1986-09-15 1989-07-27 Janssen Pharmaceutica Nv Imidazolyl methyl-substituted benzimidazole derivatives and pharmaceutical compositions
US5250517A (en) 1987-10-06 1993-10-05 Hoffmann-La Roche Inc. Renin inhibiting compounds
ES2153841T3 (es) 1992-08-13 2001-03-16 Warner Lambert Co Antagonistas de la taciquinina.
JPH0672985A (ja) 1992-08-28 1994-03-15 Ono Pharmaceut Co Ltd （チオ）ウレア誘導体
JP3118738B2 (ja) 1992-12-22 2000-12-18 小野薬品工業株式会社 （チオ）ウレア誘導体
CA2187531A1 (en) 1994-06-06 1995-12-14 David Christopher Horwell Tachykinin (nk1) receptor antagonists
DE19544687A1 (de) 1995-11-30 1997-06-05 Thomae Gmbh Dr K Aminosäurederivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
ATE207889T1 (de) * 1996-03-20 2001-11-15 Aventis Pharma Sa Trizyclische verbindungen mit wirkung auf integrine, besonders auf das alphavbeta3-integrin,verfahren zur ihrer herstellung und zwischenprodukte des verfahrens, ihre verwendung als arzneimittel und sie enthaltende pharmazeutische zusammensetzungen
NZ331480A (en) * 1997-09-04 2000-02-28 F 2-(Arylphenyl)amino-imidazoline derivatives and pharmaceutical compositions
CA2401502C (en) 2000-03-16 2010-09-21 F. Hoffmann-La Roche Ag Carboxylic acid derivatives as ip antagonists

Also Published As

Publication number Publication date
BR0109235A (pt) 2002-12-17
JP2003527368A (ja) 2003-09-16
MA27679A1 (fr) 2006-01-02
RU2002127781A (ru) 2004-03-20
AR028252A1 (es) 2003-04-30
US6693098B2 (en) 2004-02-17
NZ521028A (en) 2004-07-30
CA2401502C (en) 2010-09-21
US7056903B2 (en) 2006-06-06
PL207869B1 (pl) 2011-02-28
KR20020091135A (ko) 2002-12-05
HRP20020733A2 (en) 2005-02-28
AU2001252168B2 (en) 2007-07-12
CZ20023422A3 (cs) 2003-01-15
JP3938689B2 (ja) 2007-06-27
EP1265853A1 (en) 2002-12-18
CN1418187A (zh) 2003-05-14
US20060035870A1 (en) 2006-02-16
PL358216A1 (en) 2004-08-09
US7312230B2 (en) 2007-12-25
CN1241909C (zh) 2006-02-15
NO20024387L (no) 2002-10-21
NO20024387D0 (no) 2002-09-13
IL151478A (en) 2009-07-20
HUP0300188A3 (en) 2004-07-28
US20030220367A1 (en) 2003-11-27
WO2001068591A1 (en) 2001-09-20
AU5216801A (en) 2001-09-24
CA2401502A1 (en) 2001-09-20
MXPA02008931A (es) 2003-02-10
YU68102A (sh) 2006-01-16
US20010056100A1 (en) 2001-12-27
RU2268258C2 (ru) 2006-01-20
KR100523119B1 (ko) 2005-10-20
NO328526B1 (no) 2010-03-08
HUP0300188A2 (hu) 2003-06-28

Similar Documents

Publication Publication Date Title
HK1054924A1 (en) Carboxylic acid derivatives as ip antagonists
HK1074176A1 (en) Quinoline derivatives as neuropeptide y antagonists
MXPA02008402A (es) Derivados de quinolina como antagonistas alfa-2.
AU6785401A (en) Novel dicarboxylic acid derivatives
AU2180802A (en) Substituted 2-phenylaminoimidazoline phenyl ketone derivatives as ip antagonists
AU2002366320A1 (en) Lactams as tachykinin antagonists
AU2001231730A1 (en) Piperidyl carboxylic acids as integrin antagonists
AU2002222552A1 (en) Substituted carboxylic acid derivatives
AU2002222574A1 (en) Substituted carboxylic acid derivatives
IL148623A0 (en) Thienoisoxazolyl-and thienylpyrazolyl-phenoxy substituted propyl derivatives useful as d4 antagonists
IL152759A0 (en) Quinolonecarboxylic acid derivatives
AU2002226356A1 (en) Quinoline derivatives as nk-3 antagonists
ZA200306283B (en) Alkoxycarbonylamino heteroaryl carboxylic acid derivatives as IP antagonists.
AU2002222573A1 (en) Substituted carboxylic acid derivatives
AU6221201A (en) Propanoic acid derivatives as integrin receptor antagonists
AU2002222550A1 (en) Substituted carboxylic acid derivatives
AU2673201A (en) Alpha-arylethylpiperazine derivatives as neurokinin antagonists
AU2001265866A1 (en) Cyclic carboxylic acids as integrin antagonists
ZA200402308B (en) NOVEL a-OXYGENATED OR a-THIOLATED CARBOXYLIC ACID PENETHYLAMIDE DERIVATIVES
AU2002222549A1 (en) Substituted carboxylic acid derivatives
AU2001268490A1 (en) Dihydrostilbene alkanoic acid derivatives useful as vitronectin antagonists
PL371468A1 (en) Carboxylic acid derivative
AU2002222551A1 (en) Substituted carboxylic acid derivatives
PL357011A1 (en) Novel alpha-sulfin- and alpha-sulfonamino acid amide derivatives
GB0024695D0 (en) Cyclic carboxylic acids as intergrin antagonists

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20100308